Israel Triple Negative Breast Cancer Market to 2032

Overview

The Israel Triple Negative Breast Cancer Market is expected to reach a 160.77 USD Million by 2032 and is projected to grow at a CAGR of 11.41% from 2025 to 2032.

Revenue, 2024 (USD Million)
81.23
Forecast, 2032 (USD Million)
160.77
CAGR, 2024 - 2032
11.41%
Report Coverage
Israel

Israel Triple Negative Breast Cancer Market 2018-2032 USD Million

Israel Triple Negative Breast Cancer Market, Key Findings (2025-2032)

Market Growth and Projections:

  • Market Size (2024): 81.23 USD Million
  • Projected Market Size (2032): 160.77 USD Million
  • CAGR (2025-2032): 11.41%

Key Findings of Israel Triple Negative Breast Cancer Market

  • The Israel Triple Negative Breast Cancer Market was valued at 81.23 USD Million in 2024.
  • The Israel Triple Negative Breast Cancer Market is likely to grow at a CAGR of 11.41% during the forecast period of 2024 to 2032.
  • In 2024, the Largest segment Parenteral in Route of Administration Segment accounted for the largest share of the market with a revenue of 60.43 USD Million
  • The fastest growing segment Hospitals in End User Segment grew Fastest with a CAGR of 12.25% during the forecast period from 2024 to 2032.

Israel Triple Negative Breast Cancer Market Scope

Israel Triple Negative Breast Cancer Market Segmentation & Scope
Treatment Type
  • Others
  • Immunotherapy
  • Hormone Therapy
  • Targeted Therapy
  • Chemotherapy
Route of Administration
  • Oral
  • Parenteral
Distribution Channel
  • Online Pharmacy
  • Retail Pharmacy
  • Hospital Pharmacy
End User
  • Others
  • Homecare
  • Specialty Centers
  • Hospitals

Israel Triple Negative Breast Cancer Market Data Coverage Insights

Study Period 2024-2032
Base Year 2022
Unit Revenue in USD Million
Market Value in 2024 81.23 USD Million
Market Value in 2032 160.77 USD Million
CAGR (2025-2032) 11.41%
Historic Data 2016-2023
Market Segments Covered Treatment Type,Route of Administration,Distribution Channel,End User

Regional Insights:

  • Leading Market (2024-2032): Israel, leading in terms of revenue 81.23 USD Million in 2024
    • Key Country: Israel, leading in terms of revenue with value of 81.23 USD Million in 2024.

Segments and Scope

  • Israel Triple Negative Breast Cancer Market to 2032, By Treatment Type
    • Chemotherapy is the largest segment in Israel Triple Negative Breast Cancer Market to 2032 with a revenue of 32.38 USD Million in the year 2024.
    • Chemotherapy is the Fastest growing segment in Israel Triple Negative Breast Cancer Market to 2032 with a Growth rate of 12.21 % in forecast period 2025-2032.
  • Israel Triple Negative Breast Cancer Market to 2032, By Route of Administration
    • Parenteral is the largest segment in Israel Triple Negative Breast Cancer Market to 2032 with a revenue of 60.43 USD Million in the year 2024.
    • Parenteral is the Fastest growing segment in Israel Triple Negative Breast Cancer Market to 2032 with a Growth rate of 11.65 % in forecast period 2025-2032.
  • Israel Triple Negative Breast Cancer Market to 2032, By Distribution Channel
    • Hospital Pharmacy is the largest segment in Israel Triple Negative Breast Cancer Market to 2032 with a revenue of 44.24 USD Million in the year 2024.
    • Hospital Pharmacy is the Fastest growing segment in Israel Triple Negative Breast Cancer Market to 2032 with a Growth rate of 11.76 % in forecast period 2025-2032.
  • Israel Triple Negative Breast Cancer Market to 2032, By End User
    • Hospitals is the largest segment in Israel Triple Negative Breast Cancer Market to 2032 with a revenue of 33.70 USD Million in the year 2024.
    • Hospitals is the Fastest growing segment in Israel Triple Negative Breast Cancer Market to 2032 with a Growth rate of 12.25 % in forecast period 2025-2032.

Israel Triple Negative Breast Cancer Market Company Share Analysis

 
Israel Triple Negative Breast Cancer Market Company Share Analysis
Israel Triple Negative Breast Cancer Market Company Share Analysis

Israel Triple Negative Breast Cancer Market Geographical Sales Distribution, 2018-2032 USD Million

Israel Triple Negative Breast Cancer Market Geographical Sales Distribution, 2018-2032 USD Million

Israel Triple Negative Breast Cancer Market Company Profiling

Israel Triple Negative Breast Cancer Market Company Profiling
Frequently Asked Questions
The Israel Triple Negative Breast Cancer Market is segmented based on Segmentation Treatment Type,Route of Administration,Distribution Channel,End User.
Israel Triple Negative Breast Cancer Market was valued at USD 81.23(Revenue in USD Million) in 2022.
Israel Triple Negative Breast Cancer Market is projected to grow at a CAGR of 11.41% during the forecast period of 2024 to 2032.
The Parenteral segment is expected to dominate the Israel Triple Negative Breast Cancer Market, holding a largest market share of 60.43 USD Million in 2024

Israel Triple Negative Breast Cancer Market Scope

Israel Triple Negative Breast Cancer Market Segmentation & Scope
Treatment Type
  • Others
  • Immunotherapy
  • Hormone Therapy
  • Targeted Therapy
  • Chemotherapy
Route of Administration
  • Oral
  • Parenteral
Distribution Channel
  • Online Pharmacy
  • Retail Pharmacy
  • Hospital Pharmacy
End User
  • Others
  • Homecare
  • Specialty Centers
  • Hospitals
Frequently Asked Questions
The Israel Triple Negative Breast Cancer Market is segmented based on Segmentation Treatment Type,Route of Administration,Distribution Channel,End User.
Israel Triple Negative Breast Cancer Market was valued at USD 81.23(Revenue in USD Million) in 2022.
Israel Triple Negative Breast Cancer Market is projected to grow at a CAGR of 11.41% during the forecast period of 2024 to 2032.
The estimated market value of the Israel Triple Negative Breast Cancer Market for final year is USD 160.77 (USD Million).

Israel Triple Negative Breast Cancer Market Company Profiling

Israel Triple Negative Breast Cancer Market Company Profiling
Frequently Asked Questions
The Israel Triple Negative Breast Cancer Market is segmented based on Segmentation Treatment Type,Route of Administration,Distribution Channel,End User.
Israel Triple Negative Breast Cancer Market was valued at USD 81.23(Revenue in USD Million) in 2022.
Israel Triple Negative Breast Cancer Market is projected to grow at a CAGR of 11.41% during the forecast period of 2024 to 2032.
The estimated market value of the Israel Triple Negative Breast Cancer Market for final year is USD 160.77 (USD Million).

Related Markets

HAVE A QUESTION?

Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.